Keywords: gastritis Anti-Cancer
The statistics show that atrophic gastritis compared with other chronic gastritis, gastric evolved into the highest probability. So, is particularly important to strengthen the anti-cancer awareness.
Antimicrobial treatment recognized by the medical profession Helicobacter pylori is a pathogen of chronic gastritis, it should first antimicrobial treatment.
Atrophic gastritis often increase gastric acid concentration acid or lack of acid, the patient can be used pepsin mixture or dilute hydrochloric acid mixture; the pentagastrin small doses of intramuscular nourish, protect the gastric mucosa and promote the role of gastric parietal cells secrete acid.
Oral mucosal protective agent commonly used drugs: sucralfate, can be combined with the gastric mucosa mucin forms a protective film to protect the gastric mucosa; the stomach membrane prime, can be formed in the stomach mucosal surface membrane-like covering to reduce bile return flow of gastric mucosal damage; chlorophyll promote inflammation subsided, the protection of the gastric mucosa.
The service Weimeisu can improve human immunity, enhance the activity of detoxifying enzymes in the human body, inhibit the growth of cancer cells and prevent abnormal cell metabolism.
Treatment of bile reflux in the pyloric sphincter dysfunction due to chronic bile reflux damage the gastric mucosal barrier, resulting in chronic superficial gastritis, chronic atrophic gastritis and then developed into. Motility drugs can be applied in this case, to prevent bile reflux, so as to achieve the purpose of protection of the gastric mucosa.
Low diet gastric acid and bile reflux, should eat lean meat, poultry, fish, dairy and other high-protein, low-fat diet; should eat slowly, avoid overeating; avoid long-term drinking tea spirits and eating spicy, overheating and rough food.
Atrophic gastritis with incomplete colonic type intestinal metaplasia patients to regularly review the general atrophic gastritis 3 review regularly reviewed, incomplete colonic type intestinal metaplasia with mild dysplasia 1 In January, with moderate atypical hyperplasia 3 months.